MRNA vs. BNTX

Last updated Aug 6, 2026

MRNA (Moderna, Inc.) and BNTX (BioNTech SE) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, MRNA returned -32.90%/yr vs -24.68%/yr for BNTX. Their 0.55 correlation means they have sometimes moved together and sometimes differently.

Performance

MRNA vs. BNTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Moderna, Inc. (MRNA) and BioNTech SE (BNTX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, MRNA achieves a 90.76% return, which is significantly higher than BNTX's -3.17% return.

MRNA

• 1D: -1.29%
• 1M: -31.23%
• 6M: 31.53%
• YTD: 90.76%
• 1Y: 104.79%
• 3Y*: -19.59%
• 5Y*: -32.90%
• 10Y*: —
• ALL TIME*: 13.04%

BNTX

• 1D: 0.91%
• 1M: -1.86%
• 6M: -15.25%
• YTD: -3.17%
• 1Y: -17.01%
• 3Y*: -4.69%
• 5Y*: -24.68%
• 10Y*: —
• ALL TIME*: 29.12%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
BNTX BioNTech SE	$95.84M	$81.22M	$85.92M
MRNA Moderna, Inc.	$282.14M	$344.16M	$450.25M

MRNA vs. BNTX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
MRNA Moderna, Inc.	90.76%	-29.08%	-58.19%	-44.63%	-29.28%	143.11%	434.10%	37.75%
BNTX BioNTech SE	-3.17%	-16.45%	7.97%	-29.74%	-40.40%	216.24%	140.61%	105.33%

Correlation

The correlation between MRNA and BNTX is 0.54, which is moderate. They have sometimes moved together and sometimes differently, sharing some price drivers without tracking each other closely.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.54
Correlation (3Y) Balances recent behavior with more history.	0.58
Correlation (5Y) Shows whether the relationship held over a longer period.	0.67
Correlation (All Time) Calculated using the full available price history since Oct 10, 2019	0.55

The correlation between MRNA and BNTX shifts across timeframes, from 0.54 (1 year) to 0.67 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap MRNA : $22.32B BNTX : $23.16B
EPS MRNA : -$8.01 BNTX : -€5.12
PS Ratio MRNA : 9.93 BNTX : 7.02
PB Ratio MRNA : 3.29 BNTX : 1.08
Total Revenue (TTM) MRNA : $2.23B BNTX : €2.80B
Gross Profit (TTM) MRNA : -$280.00M BNTX : €2.05B
EBITDA (TTM) MRNA : -$2.94B BNTX : -€815.04M

Return for Risk

MRNA vs. BNTX — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

MRNA

MRNA Risk / Return Rank: 84
MRNA Sharpe Ratio Rank: 84
MRNA Sortino Ratio Rank: 84
MRNA Omega Ratio Rank: 79
MRNA Calmar Ratio Rank: 86
MRNA Martin Ratio Rank: 86

BNTX

BNTX Risk / Return Rank: 22
BNTX Sharpe Ratio Rank: 24
BNTX Sortino Ratio Rank: 23
BNTX Omega Ratio Rank: 22
BNTX Calmar Ratio Rank: 21
BNTX Martin Ratio Rank: 19

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

MRNA vs. BNTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Moderna, Inc. (MRNA) and BioNTech SE (BNTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	MRNA	BNTX	Difference
Sharpe ratio: Return per unit of total volatility	1.54	-0.41	+1.95
Sortino ratio: Return per unit of downside risk	2.34	-0.32	+2.66
Omega ratio: Gain probability vs. loss probability	1.27	0.95	+0.32
Calmar ratio: Return relative to maximum drawdown	3.11	-0.57	+3.68
Martin ratio: Return relative to average drawdown	8.01	-1.02	+9.03

MRNA vs. BNTX - Sharpe Ratio Comparison

The current MRNA Sharpe Ratio is 1.54, which is higher than the BNTX Sharpe Ratio of -0.41. The chart below compares the historical Sharpe Ratios of MRNA and BNTX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

MRNA vs. BNTX - Drawdown Comparison

The maximum MRNA drawdown since its inception was -95.38%, which is greater than BNTX's maximum drawdown of -82.08%. Use the drawdown chart below to compare losses from any high point for MRNA and BNTX.

Drawdown Indicators

	MRNA	BNTX	Difference
Max Drawdown Largest peak-to-trough decline	-95.38%	-82.08%	-13.30%
Max Drawdown (1Y) Largest decline over 1 year	-33.90%	-29.71%	-4.19%
Max Drawdown (3Y) Largest decline over 3 years	-86.58%	-37.35%	-49.23%
Max Drawdown (5Y) Largest decline over 5 years	-95.38%	-82.08%	-13.30%
Current Drawdown Current decline from peak	-88.39%	-78.92%	-9.47%
Average Drawdown Average peak-to-trough decline	-57.62%	-56.72%	-0.90%
Ulcer Index Depth and duration of drawdowns from previous peaks	13.15%	16.63%	-3.48%

Volatility

MRNA vs. BNTX - Volatility Comparison

Moderna, Inc. (MRNA) has a higher volatility of 19.61% compared to BioNTech SE (BNTX) at 6.21%. This indicates that MRNA's price experiences larger fluctuations and is considered to be riskier than BNTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	MRNA	BNTX	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.61%	6.21%	+13.40%
Volatility (6M) Calculated over the trailing 6-month period	47.84%	31.78%	+16.06%
Volatility (1Y) Calculated over the trailing 1-year period	68.65%	41.31%	+27.34%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	66.73%	53.75%	+12.98%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	72.34%	75.64%	-3.30%

Dividends

MRNA vs. BNTX - Dividend Comparison

Neither MRNA nor BNTX has paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022
BNTX BioNTech SE	0.00%	0.00%	0.00%	0.00%	2.43%
MRNA Moderna, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

Frequently Asked Questions

Can I hold both MRNA and BNTX in my portfolio?

MRNA and BNTX have a correlation of 0.54, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, MRNA or BNTX?

MRNA has higher volatility (19.61%) compared to BNTX (6.21%). In terms of maximum drawdown, MRNA dropped -95.38% vs BNTX's -82.08%.

Which has better risk-adjusted returns?

MRNA currently has the higher Sharpe Ratio (1.54 vs -0.41), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.